
The following have been reloaded with a version change:
  1) GCCcore/8.3.0 => GCCcore/9.3.0
  2) binutils/2.32-GCCcore-8.3.0 => binutils/2.34-GCCcore-9.3.0
  3) zlib/1.2.11-GCCcore-8.3.0 => zlib/1.2.11-GCCcore-9.3.0

2021-02-04 18:19:38 | INFO | fairseq_cli.train | Namespace(activation_dropout=0.0, activation_fn='relu', adam_betas='(0.9, 0.98)', adam_eps=1e-08, adaptive_input=False, adaptive_softmax_cutoff=None, adaptive_softmax_dropout=0, all_gather_list_size=16384, arch='transformer_vaswani_wmt_en_de_big', attention_dropout=0.0, best_checkpoint_metric='bleu', bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', clip_norm=0.0, cpu=False, criterion='label_smoothed_cross_entropy', cross_self_attention=False, curriculum=0, data='../../../data-bin/phrase4_0.5_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoder_attention_heads=16, decoder_embed_dim=1024, decoder_embed_path=None, decoder_ffn_embed_dim=4096, decoder_input_dim=1024, decoder_layerdrop=0, decoder_layers=6, decoder_layers_to_keep=None, decoder_learned_pos=False, decoder_normalize_before=False, decoder_output_dim=1024, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', dropout=0.2, empty_cache_freq=0, encoder_attention_heads=16, encoder_embed_dim=1024, encoder_embed_path=None, encoder_ffn_embed_dim=8192, encoder_layerdrop=0, encoder_layers=6, encoder_layers_to_keep=None, encoder_learned_pos=False, encoder_normalize_before=False, eval_bleu=True, eval_bleu_args='{"beam": 5, "max_len_a": 1.2, "max_len_b": 10}', eval_bleu_detok='moses', eval_bleu_detok_args=None, eval_bleu_print_samples=True, eval_bleu_remove_bpe='@@ ', eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, fixed_validation_seed=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, label_smoothing=0.1, layernorm_embedding=False, left_pad_source='True', left_pad_target='False', load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr=[5e-05], lr_scheduler='inverse_sqrt', max_epoch=20, max_sentences=None, max_sentences_valid=None, max_source_positions=1024, max_target_positions=1024, max_tokens=4096, max_tokens_valid=4096, max_update=0, maximize_best_checkpoint_metric=True, memory_efficient_bf16=False, memory_efficient_fp16=False, min_loss_scale=0.0001, min_lr=-1, model_parallel_size=1, no_cross_attention=False, no_epoch_checkpoints=True, no_last_checkpoints=False, no_progress_bar=False, no_save=False, no_save_optimizer_state=False, no_scale_embedding=False, no_seed_provided=True, no_token_positional_embeddings=False, nprocs_per_node=1, num_batch_buckets=0, num_workers=1, optimizer='adam', optimizer_overrides='{}', patience=-1, profile=False, quant_noise_pq=0, quant_noise_pq_block_size=8, quant_noise_scalar=0, quantization_config_path=None, required_batch_size_multiple=8, reset_dataloader=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=True, restore_file='../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt', save_dir='../checkpoints/EMEA_p_4_1', save_interval=1, save_interval_updates=0, scoring='bleu', seed=1, sentence_avg=False, share_all_embeddings=False, share_decoder_input_output_embed=True, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, stop_time_hours=0, target_lang=None, task='translation', tensorboard_logdir='', threshold_loss_scale=None, tie_adaptive_weights=False, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, update_freq=[1], upsample_primary=1, use_bmuf=False, use_old_adam=False, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, warmup_init_lr=-1, warmup_updates=4000, weight_decay=0.0001)
2021-02-04 18:19:39 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-02-04 18:19:39 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-02-04 18:19:39 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase4_0.5_EMEA/valid.de-en.de
2021-02-04 18:19:39 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase4_0.5_EMEA/valid.de-en.en
2021-02-04 18:19:39 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase4_0.5_EMEA valid de-en 151 examples
2021-02-04 18:19:45 | INFO | fairseq_cli.train | TransformerModel(
  (encoder): TransformerEncoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
  )
  (decoder): TransformerDecoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
    (output_projection): Linear(in_features=1024, out_features=42024, bias=False)
  )
)
2021-02-04 18:19:45 | INFO | fairseq_cli.train | model transformer_vaswani_wmt_en_de_big, criterion LabelSmoothedCrossEntropyCriterion
2021-02-04 18:19:45 | INFO | fairseq_cli.train | num. model params: 312778752 (num. trained: 312778752)
2021-02-04 18:19:53 | INFO | fairseq.trainer | detected shared parameter: decoder.embed_tokens.weight <- decoder.output_projection.weight
2021-02-04 18:19:53 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-04 18:19:53 | INFO | fairseq.utils | rank   0: capabilities =  7.0  ; total memory = 32.000 GB ; name = GRID V100D-32Q                          
2021-02-04 18:19:53 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-04 18:19:53 | INFO | fairseq_cli.train | training on 1 devices (GPUs/TPUs)
2021-02-04 18:19:53 | INFO | fairseq_cli.train | max tokens per GPU = 4096 and max sentences per GPU = None
2021-02-04 18:20:02 | INFO | fairseq.trainer | loaded checkpoint ../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt (epoch 16 @ 0 updates)
2021-02-04 18:20:02 | INFO | fairseq.trainer | loading train data for epoch 1
2021-02-04 18:20:02 | INFO | fairseq.data.data_utils | loaded 93981 examples from: ../../../data-bin/phrase4_0.5_EMEA/train.de-en.de
2021-02-04 18:20:02 | INFO | fairseq.data.data_utils | loaded 93981 examples from: ../../../data-bin/phrase4_0.5_EMEA/train.de-en.en
2021-02-04 18:20:02 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase4_0.5_EMEA train de-en 93981 examples
2021-02-04 18:20:03 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-04 18:20:04 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 64.0
2021-02-04 18:20:05 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 32.0
2021-02-04 18:20:05 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 16.0
2021-02-04 18:20:05 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 8.0
2021-02-04 18:20:05 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 4.0
2021-02-04 18:20:05 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 2.0
2021-02-04 18:20:06 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 1.0
2021-02-04 18:20:24 | INFO | train_inner | epoch 001:    107 / 118 loss=4.297, nll_loss=2.682, ppl=6.42, wps=17762.6, ups=5.22, wpb=3403.8, bsz=793.8, num_updates=100, lr=1.25e-06, gnorm=19.208, loss_scale=1, train_wall=19, wall=31
2021-02-04 18:20:26 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:20:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:20:28 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:20:29 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast acting insulin and can be used together with long acting insulin preparations.
2021-02-04 18:20:29 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:20:30 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood sugar control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:20:30 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:20:33 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two studies with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (one study with 182 patients). In the studies, actrapid was compared to a human insulin analogue (insulin aspart) by measuring the concentration in the blood of a substance called glycosylated hemoglobin (HbA1c), which indicates how well the blood sugar is regulated. What benefit did actrapid show in these studies? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-04 18:20:33 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:20:33 | INFO | valid | epoch 001 | valid on 'valid' subset | loss 3.936 | nll_loss 2.223 | ppl 4.67 | bleu 31.64 | wps 724.4 | wpb 1083 | bsz 37.8 | num_updates 111
2021-02-04 18:20:33 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:20:47 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 1 @ 111 updates, score 31.64) (writing took 14.463513823226094 seconds)
2021-02-04 18:20:47 | INFO | fairseq_cli.train | end of epoch 1 (average epoch stats below)
2021-02-04 18:20:47 | INFO | train | epoch 001 | loss 4.318 | nll_loss 2.705 | ppl 6.52 | wps 8850.7 | ups 2.62 | wpb 3371.2 | bsz 789.8 | num_updates 111 | lr 1.3875e-06 | gnorm 18.873 | loss_scale 2 | train_wall 23 | wall 54
2021-02-04 18:20:47 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-04 18:21:04 | INFO | train_inner | epoch 002:     89 / 118 loss=3.837, nll_loss=2.173, ppl=4.51, wps=8246.9, ups=2.52, wpb=3277.4, bsz=741.1, num_updates=200, lr=2.5e-06, gnorm=10.941, loss_scale=1, train_wall=19, wall=71
2021-02-04 18:21:10 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:21:10 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:21:10 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:21:11 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast acting insulin and can be used together with long acting insulin preparations.
2021-02-04 18:21:11 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:21:12 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood sugar control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:21:12 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:21:14 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes, in which the pancreas is unable to produce insulin (two studies with 1 954 patients), and in patients with type 2 diabetes, in which the body is unable to process insulin effectively (a study with 182 patients). In the studies, actrapid was compared to a human insulin analogue (insulin aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is regulated. What benefit has actrapid shown in these studies? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-04 18:21:14 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:21:14 | INFO | valid | epoch 002 | valid on 'valid' subset | loss 3.877 | nll_loss 2.164 | ppl 4.48 | bleu 34.78 | wps 891.2 | wpb 1083 | bsz 37.8 | num_updates 229 | best_bleu 34.78
2021-02-04 18:21:14 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:21:31 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 2 @ 229 updates, score 34.78) (writing took 16.10094198025763 seconds)
2021-02-04 18:21:31 | INFO | fairseq_cli.train | end of epoch 2 (average epoch stats below)
2021-02-04 18:21:31 | INFO | train | epoch 002 | loss 3.706 | nll_loss 2.029 | ppl 4.08 | wps 9220 | ups 2.73 | wpb 3371.3 | bsz 796.4 | num_updates 229 | lr 2.8625e-06 | gnorm 9.576 | loss_scale 1 | train_wall 22 | wall 97
2021-02-04 18:21:31 | INFO | fairseq_cli.train | begin training epoch 2
2021-02-04 18:21:44 | INFO | train_inner | epoch 003:     71 / 118 loss=3.394, nll_loss=1.682, ppl=3.21, wps=8812, ups=2.49, wpb=3540, bsz=879, num_updates=300, lr=3.75e-06, gnorm=5.632, loss_scale=1, train_wall=19, wall=111
2021-02-04 18:21:53 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:21:54 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:21:54 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:21:54 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:21:54 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:21:55 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:21:55 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:21:59 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, actrapid was compared to a human insulin analogue (insulin aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is regulated. What benefit has actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-04 18:21:59 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:21:59 | INFO | valid | epoch 003 | valid on 'valid' subset | loss 3.795 | nll_loss 2.077 | ppl 4.22 | bleu 36.43 | wps 732.5 | wpb 1083 | bsz 37.8 | num_updates 347 | best_bleu 36.43
2021-02-04 18:21:59 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:22:16 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 3 @ 347 updates, score 36.43) (writing took 17.082588345743716 seconds)
2021-02-04 18:22:16 | INFO | fairseq_cli.train | end of epoch 3 (average epoch stats below)
2021-02-04 18:22:16 | INFO | train | epoch 003 | loss 3.312 | nll_loss 1.589 | ppl 3.01 | wps 8799.3 | ups 2.61 | wpb 3371.3 | bsz 796.4 | num_updates 347 | lr 4.3375e-06 | gnorm 4.817 | loss_scale 1 | train_wall 22 | wall 142
2021-02-04 18:22:16 | INFO | fairseq_cli.train | begin training epoch 3
2021-02-04 18:22:26 | INFO | train_inner | epoch 004:     53 / 118 loss=3.249, nll_loss=1.516, ppl=2.86, wps=7887.5, ups=2.41, wpb=3266.3, bsz=736.9, num_updates=400, lr=5e-06, gnorm=4.298, loss_scale=1, train_wall=19, wall=152
2021-02-04 18:22:38 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:22:39 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:22:39 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:22:39 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:22:39 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:22:40 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:22:40 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:22:44 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared to a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is regulated.What benefit has actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-04 18:22:44 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:22:44 | INFO | valid | epoch 004 | valid on 'valid' subset | loss 3.728 | nll_loss 1.99 | ppl 3.97 | bleu 36.34 | wps 719.7 | wpb 1083 | bsz 37.8 | num_updates 465 | best_bleu 36.43
2021-02-04 18:22:44 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:22:51 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 4 @ 465 updates, score 36.34) (writing took 6.82468122150749 seconds)
2021-02-04 18:22:51 | INFO | fairseq_cli.train | end of epoch 4 (average epoch stats below)
2021-02-04 18:22:51 | INFO | train | epoch 004 | loss 3.121 | nll_loss 1.371 | ppl 2.59 | wps 11406.9 | ups 3.38 | wpb 3371.3 | bsz 796.4 | num_updates 465 | lr 5.8125e-06 | gnorm 3.824 | loss_scale 1 | train_wall 22 | wall 177
2021-02-04 18:22:51 | INFO | fairseq_cli.train | begin training epoch 4
2021-02-04 18:22:57 | INFO | train_inner | epoch 005:     35 / 118 loss=3.128, nll_loss=1.377, ppl=2.6, wps=10563.8, ups=3.18, wpb=3322.6, bsz=813.3, num_updates=500, lr=6.25e-06, gnorm=3.745, loss_scale=1, train_wall=19, wall=184
2021-02-04 18:23:13 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:23:14 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:23:14 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:23:14 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:23:14 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:23:15 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:23:15 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:23:19 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared to a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is regulated.What benefit has actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6-month treatment with Actrapid.
2021-02-04 18:23:19 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:23:19 | INFO | valid | epoch 005 | valid on 'valid' subset | loss 3.694 | nll_loss 1.948 | ppl 3.86 | bleu 37.73 | wps 730.1 | wpb 1083 | bsz 37.8 | num_updates 583 | best_bleu 37.73
2021-02-04 18:23:19 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:23:37 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 5 @ 583 updates, score 37.73) (writing took 18.24305867217481 seconds)
2021-02-04 18:23:37 | INFO | fairseq_cli.train | end of epoch 5 (average epoch stats below)
2021-02-04 18:23:37 | INFO | train | epoch 005 | loss 2.995 | nll_loss 1.226 | ppl 2.34 | wps 8602.9 | ups 2.55 | wpb 3371.3 | bsz 796.4 | num_updates 583 | lr 7.2875e-06 | gnorm 3.506 | loss_scale 1 | train_wall 22 | wall 223
2021-02-04 18:23:37 | INFO | fairseq_cli.train | begin training epoch 5
2021-02-04 18:23:40 | INFO | train_inner | epoch 006:     17 / 118 loss=2.909, nll_loss=1.129, ppl=2.19, wps=7973.4, ups=2.33, wpb=3425.3, bsz=802.3, num_updates=600, lr=7.5e-06, gnorm=3.354, loss_scale=1, train_wall=19, wall=227
2021-02-04 18:23:59 | INFO | train_inner | epoch 006:    117 / 118 loss=2.868, nll_loss=1.081, ppl=2.12, wps=17792.6, ups=5.3, wpb=3359.7, bsz=801.2, num_updates=700, lr=8.75e-06, gnorm=3.255, loss_scale=1, train_wall=19, wall=246
2021-02-04 18:23:59 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:24:00 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:24:00 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:24:01 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used with long-acting insulin preparations.
2021-02-04 18:24:01 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:24:02 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:24:02 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:24:04 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well blood glucose is regulated.What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during 6 months of treatment with Actrapid.
2021-02-04 18:24:04 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:24:04 | INFO | valid | epoch 006 | valid on 'valid' subset | loss 3.679 | nll_loss 1.933 | ppl 3.82 | bleu 38.88 | wps 901.6 | wpb 1083 | bsz 37.8 | num_updates 701 | best_bleu 38.88
2021-02-04 18:24:04 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:24:22 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 6 @ 701 updates, score 38.88) (writing took 18.048379864543676 seconds)
2021-02-04 18:24:22 | INFO | fairseq_cli.train | end of epoch 6 (average epoch stats below)
2021-02-04 18:24:22 | INFO | train | epoch 006 | loss 2.895 | nll_loss 1.112 | ppl 2.16 | wps 8818 | ups 2.62 | wpb 3371.3 | bsz 796.4 | num_updates 701 | lr 8.7625e-06 | gnorm 3.278 | loss_scale 1 | train_wall 22 | wall 269
2021-02-04 18:24:22 | INFO | fairseq_cli.train | begin training epoch 6
2021-02-04 18:24:41 | INFO | train_inner | epoch 007:     99 / 118 loss=2.81, nll_loss=1.014, ppl=2.02, wps=8080.3, ups=2.4, wpb=3366.6, bsz=788.9, num_updates=800, lr=1e-05, gnorm=3.024, loss_scale=1, train_wall=19, wall=287
2021-02-04 18:24:44 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:24:45 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:24:45 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:24:46 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used in conjunction with long-acting insulin products.
2021-02-04 18:24:46 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:24:47 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy and is usually reversible.
2021-02-04 18:24:47 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:24:49 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well blood glucose is regulated.What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6-month treatment with Actrapid.
2021-02-04 18:24:49 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:24:49 | INFO | valid | epoch 007 | valid on 'valid' subset | loss 3.674 | nll_loss 1.92 | ppl 3.78 | bleu 39.6 | wps 892.6 | wpb 1083 | bsz 37.8 | num_updates 819 | best_bleu 39.6
2021-02-04 18:24:49 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:25:07 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 7 @ 819 updates, score 39.6) (writing took 17.85109727922827 seconds)
2021-02-04 18:25:07 | INFO | fairseq_cli.train | end of epoch 7 (average epoch stats below)
2021-02-04 18:25:07 | INFO | train | epoch 007 | loss 2.808 | nll_loss 1.013 | ppl 2.02 | wps 8858.5 | ups 2.63 | wpb 3371.3 | bsz 796.4 | num_updates 819 | lr 1.02375e-05 | gnorm 3.052 | loss_scale 1 | train_wall 22 | wall 314
2021-02-04 18:25:07 | INFO | fairseq_cli.train | begin training epoch 7
2021-02-04 18:25:22 | INFO | train_inner | epoch 008:     81 / 118 loss=2.771, nll_loss=0.972, ppl=1.96, wps=8090.9, ups=2.41, wpb=3357.3, bsz=797.7, num_updates=900, lr=1.125e-05, gnorm=3.14, loss_scale=1, train_wall=19, wall=329
2021-02-04 18:25:29 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:25:30 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:25:30 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:25:31 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:25:31 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:25:32 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy that are usually reversible.
2021-02-04 18:25:32 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:25:34 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is controlled. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-04 18:25:34 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:25:34 | INFO | valid | epoch 008 | valid on 'valid' subset | loss 3.672 | nll_loss 1.916 | ppl 3.77 | bleu 40.68 | wps 905.8 | wpb 1083 | bsz 37.8 | num_updates 937 | best_bleu 40.68
2021-02-04 18:25:34 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:25:56 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 8 @ 937 updates, score 40.68) (writing took 21.775529796257615 seconds)
2021-02-04 18:25:56 | INFO | fairseq_cli.train | end of epoch 8 (average epoch stats below)
2021-02-04 18:25:56 | INFO | train | epoch 008 | loss 2.728 | nll_loss 0.921 | ppl 1.89 | wps 8148.7 | ups 2.42 | wpb 3371.3 | bsz 796.4 | num_updates 937 | lr 1.17125e-05 | gnorm 2.937 | loss_scale 1 | train_wall 22 | wall 362
2021-02-04 18:25:56 | INFO | fairseq_cli.train | begin training epoch 8
2021-02-04 18:26:08 | INFO | train_inner | epoch 009:     63 / 118 loss=2.645, nll_loss=0.827, ppl=1.77, wps=7589.2, ups=2.19, wpb=3458.6, bsz=801.9, num_updates=1000, lr=1.25e-05, gnorm=2.407, loss_scale=1, train_wall=19, wall=374
2021-02-04 18:26:18 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:26:19 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:26:19 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:26:20 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:26:20 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:26:20 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy that is usually reversible.
2021-02-04 18:26:20 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:26:23 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapid with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is controlled. What benefit has actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with actrapid.
2021-02-04 18:26:23 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:26:23 | INFO | valid | epoch 009 | valid on 'valid' subset | loss 3.716 | nll_loss 1.963 | ppl 3.9 | bleu 40.7 | wps 923.1 | wpb 1083 | bsz 37.8 | num_updates 1055 | best_bleu 40.7
2021-02-04 18:26:23 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:26:43 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 9 @ 1055 updates, score 40.7) (writing took 20.00907020457089 seconds)
2021-02-04 18:26:43 | INFO | fairseq_cli.train | end of epoch 9 (average epoch stats below)
2021-02-04 18:26:43 | INFO | train | epoch 009 | loss 2.655 | nll_loss 0.84 | ppl 1.79 | wps 8446.2 | ups 2.51 | wpb 3371.3 | bsz 796.4 | num_updates 1055 | lr 1.31875e-05 | gnorm 2.735 | loss_scale 1 | train_wall 22 | wall 409
2021-02-04 18:26:43 | INFO | fairseq_cli.train | begin training epoch 9
2021-02-04 18:26:51 | INFO | train_inner | epoch 010:     45 / 118 loss=2.651, nll_loss=0.834, ppl=1.78, wps=7476.9, ups=2.3, wpb=3256.3, bsz=795.5, num_updates=1100, lr=1.375e-05, gnorm=2.889, loss_scale=1, train_wall=19, wall=418
2021-02-04 18:27:05 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:27:06 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:27:06 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:27:06 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:27:06 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:27:07 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy that is usually reversible.
2021-02-04 18:27:07 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:27:10 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (Insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates well controlled glucose. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-04 18:27:10 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:27:10 | INFO | valid | epoch 010 | valid on 'valid' subset | loss 3.689 | nll_loss 1.934 | ppl 3.82 | bleu 42.04 | wps 925.8 | wpb 1083 | bsz 37.8 | num_updates 1173 | best_bleu 42.04
2021-02-04 18:27:10 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:27:27 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 10 @ 1173 updates, score 42.04) (writing took 17.2557770665735 seconds)
2021-02-04 18:27:27 | INFO | fairseq_cli.train | end of epoch 10 (average epoch stats below)
2021-02-04 18:27:27 | INFO | train | epoch 010 | loss 2.587 | nll_loss 0.762 | ppl 1.7 | wps 9006.5 | ups 2.67 | wpb 3371.3 | bsz 796.4 | num_updates 1173 | lr 1.46625e-05 | gnorm 2.547 | loss_scale 1 | train_wall 22 | wall 454
2021-02-04 18:27:27 | INFO | fairseq_cli.train | begin training epoch 10
2021-02-04 18:27:32 | INFO | train_inner | epoch 011:     27 / 118 loss=2.582, nll_loss=0.758, ppl=1.69, wps=8412.2, ups=2.45, wpb=3439.2, bsz=850.8, num_updates=1200, lr=1.5e-05, gnorm=2.708, loss_scale=1, train_wall=19, wall=459
2021-02-04 18:27:49 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:27:50 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:27:50 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:27:51 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:27:51 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:27:52 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy that are usually reversible.
2021-02-04 18:27:52 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:27:54 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was investigated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapid with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is controlled. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-04 18:27:54 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:27:54 | INFO | valid | epoch 011 | valid on 'valid' subset | loss 3.736 | nll_loss 1.99 | ppl 3.97 | bleu 42.07 | wps 910.6 | wpb 1083 | bsz 37.8 | num_updates 1291 | best_bleu 42.07
2021-02-04 18:27:54 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:28:13 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_best.pt (epoch 11 @ 1291 updates, score 42.07) (writing took 18.630198806524277 seconds)
2021-02-04 18:28:13 | INFO | fairseq_cli.train | end of epoch 11 (average epoch stats below)
2021-02-04 18:28:13 | INFO | train | epoch 011 | loss 2.529 | nll_loss 0.696 | ppl 1.62 | wps 8719.9 | ups 2.59 | wpb 3371.3 | bsz 796.4 | num_updates 1291 | lr 1.61375e-05 | gnorm 2.459 | loss_scale 1 | train_wall 22 | wall 499
2021-02-04 18:28:13 | INFO | fairseq_cli.train | begin training epoch 11
2021-02-04 18:28:14 | INFO | train_inner | epoch 012:      9 / 118 loss=2.5, nll_loss=0.661, ppl=1.58, wps=7925.9, ups=2.38, wpb=3335.5, bsz=722.1, num_updates=1300, lr=1.625e-05, gnorm=2.279, loss_scale=1, train_wall=19, wall=501
2021-02-04 18:28:33 | INFO | train_inner | epoch 012:    109 / 118 loss=2.474, nll_loss=0.635, ppl=1.55, wps=17979.9, ups=5.26, wpb=3419, bsz=842, num_updates=1400, lr=1.75e-05, gnorm=2.435, loss_scale=1, train_wall=19, wall=520
2021-02-04 18:28:35 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:28:36 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:28:36 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:28:36 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:28:36 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:28:37 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy that are usually reversible.
2021-02-04 18:28:37 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:28:40 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was evaluated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is controlled. What benefit has actrapide shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with actrapide.
2021-02-04 18:28:40 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:28:40 | INFO | valid | epoch 012 | valid on 'valid' subset | loss 3.799 | nll_loss 2.054 | ppl 4.15 | bleu 40.76 | wps 920.6 | wpb 1083 | bsz 37.8 | num_updates 1409 | best_bleu 42.07
2021-02-04 18:28:40 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:28:45 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 12 @ 1409 updates, score 40.76) (writing took 5.774733523838222 seconds)
2021-02-04 18:28:45 | INFO | fairseq_cli.train | end of epoch 12 (average epoch stats below)
2021-02-04 18:28:45 | INFO | train | epoch 012 | loss 2.475 | nll_loss 0.635 | ppl 1.55 | wps 12164.1 | ups 3.61 | wpb 3371.3 | bsz 796.4 | num_updates 1409 | lr 1.76125e-05 | gnorm 2.433 | loss_scale 1 | train_wall 22 | wall 532
2021-02-04 18:28:45 | INFO | fairseq_cli.train | begin training epoch 12
2021-02-04 18:29:03 | INFO | train_inner | epoch 013:     91 / 118 loss=2.443, nll_loss=0.597, ppl=1.51, wps=11338.8, ups=3.41, wpb=3322.7, bsz=756.4, num_updates=1500, lr=1.875e-05, gnorm=2.352, loss_scale=1, train_wall=19, wall=549
2021-02-04 18:29:08 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:29:08 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:29:08 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:29:09 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:29:09 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:29:10 | INFO | fairseq.tasks.translation | example hypothesis: Nervous disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy that are usually reversible.
2021-02-04 18:29:10 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:29:12 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was evaluated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (insulin Aspart) by measuring for six months the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is controlled. What benefit has actrapide shown in these trials? Concentrations of HbA1c remained relatively stable during 6 months of treatment with actrapide.
2021-02-04 18:29:12 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:29:12 | INFO | valid | epoch 013 | valid on 'valid' subset | loss 3.824 | nll_loss 2.086 | ppl 4.25 | bleu 41.21 | wps 901.4 | wpb 1083 | bsz 37.8 | num_updates 1527 | best_bleu 42.07
2021-02-04 18:29:12 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:29:19 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 13 @ 1527 updates, score 41.21) (writing took 6.860358807258308 seconds)
2021-02-04 18:29:19 | INFO | fairseq_cli.train | end of epoch 13 (average epoch stats below)
2021-02-04 18:29:19 | INFO | train | epoch 013 | loss 2.431 | nll_loss 0.586 | ppl 1.5 | wps 11697.3 | ups 3.47 | wpb 3371.3 | bsz 796.4 | num_updates 1527 | lr 1.90875e-05 | gnorm 2.264 | loss_scale 1 | train_wall 22 | wall 566
2021-02-04 18:29:19 | INFO | fairseq_cli.train | begin training epoch 13
2021-02-04 18:29:33 | INFO | train_inner | epoch 014:     73 / 118 loss=2.363, nll_loss=0.511, ppl=1.42, wps=10993.9, ups=3.27, wpb=3363.4, bsz=781.2, num_updates=1600, lr=2e-05, gnorm=1.929, loss_scale=1, train_wall=19, wall=580
2021-02-04 18:29:42 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:29:42 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:29:42 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:29:43 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:29:43 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:29:44 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy that is usually reversible.
2021-02-04 18:29:44 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:29:46 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was evaluated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (insulin Aspart) by measuring levels in the blood of a substance called glycosylated haemoglobin (HbA1c) that indicates how well blood sugar is controlled. What benefit has actrapide shown in these trials? Concentrations of HbA1c remained relatively stable during 6 months of treatment with actrapide.
2021-02-04 18:29:46 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:29:46 | INFO | valid | epoch 014 | valid on 'valid' subset | loss 3.855 | nll_loss 2.127 | ppl 4.37 | bleu 39.93 | wps 937.3 | wpb 1083 | bsz 37.8 | num_updates 1645 | best_bleu 42.07
2021-02-04 18:29:46 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:29:52 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 14 @ 1645 updates, score 39.93) (writing took 5.593415337614715 seconds)
2021-02-04 18:29:52 | INFO | fairseq_cli.train | end of epoch 14 (average epoch stats below)
2021-02-04 18:29:52 | INFO | train | epoch 014 | loss 2.386 | nll_loss 0.536 | ppl 1.45 | wps 12244.9 | ups 3.63 | wpb 3371.3 | bsz 796.4 | num_updates 1645 | lr 2.05625e-05 | gnorm 2.073 | loss_scale 1 | train_wall 22 | wall 598
2021-02-04 18:29:52 | INFO | fairseq_cli.train | begin training epoch 14
2021-02-04 18:30:02 | INFO | train_inner | epoch 015:     55 / 118 loss=2.387, nll_loss=0.536, ppl=1.45, wps=11801.2, ups=3.44, wpb=3434.3, bsz=823.4, num_updates=1700, lr=2.125e-05, gnorm=2.021, loss_scale=1, train_wall=19, wall=609
2021-02-04 18:30:14 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:30:15 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:30:15 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:30:15 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is a fast-acting insulin and can be used together with long-acting insulin products.
2021-02-04 18:30:15 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:30:16 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy that is usually reversible.
2021-02-04 18:30:16 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:30:19 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was evaluated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (insulin Aspart) by measuring levels in the blood of a substance called glycosylated haemoglobin (HbA1c) that indicates how well blood sugar is controlled. What benefit has actrapide shown in these trials? Concentrations of HbA1c remained relatively stable during 6 months of treatment with actrapide.
2021-02-04 18:30:19 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:30:19 | INFO | valid | epoch 015 | valid on 'valid' subset | loss 3.951 | nll_loss 2.234 | ppl 4.7 | bleu 40.81 | wps 929.3 | wpb 1083 | bsz 37.8 | num_updates 1763 | best_bleu 42.07
2021-02-04 18:30:19 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:30:25 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 15 @ 1763 updates, score 40.81) (writing took 5.901008216664195 seconds)
2021-02-04 18:30:25 | INFO | fairseq_cli.train | end of epoch 15 (average epoch stats below)
2021-02-04 18:30:25 | INFO | train | epoch 015 | loss 2.354 | nll_loss 0.5 | ppl 1.41 | wps 12128.5 | ups 3.6 | wpb 3371.3 | bsz 796.4 | num_updates 1763 | lr 2.20375e-05 | gnorm 2.018 | loss_scale 1 | train_wall 22 | wall 631
2021-02-04 18:30:25 | INFO | fairseq_cli.train | begin training epoch 15
2021-02-04 18:30:32 | INFO | train_inner | epoch 016:     37 / 118 loss=2.346, nll_loss=0.491, ppl=1.41, wps=11165.6, ups=3.4, wpb=3282.4, bsz=776.9, num_updates=1800, lr=2.25e-05, gnorm=2.073, loss_scale=1, train_wall=19, wall=638
2021-02-04 18:30:47 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:30:48 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:30:48 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:30:48 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is fast-acting insulin and can be used with long-acting insulin products.
2021-02-04 18:30:48 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:30:49 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy that are usually reversible.
2021-02-04 18:30:49 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:30:52 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was evaluated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c) that indicates how well blood sugar is controlled. What benefit has Actrapide shown in these trials? Concentrations of HbA1c remained relatively stable during 6 months of treatment with Actrapide.
2021-02-04 18:30:52 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:30:52 | INFO | valid | epoch 016 | valid on 'valid' subset | loss 3.926 | nll_loss 2.213 | ppl 4.64 | bleu 40.71 | wps 927 | wpb 1083 | bsz 37.8 | num_updates 1881 | best_bleu 42.07
2021-02-04 18:30:52 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:30:58 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 16 @ 1881 updates, score 40.71) (writing took 5.894585910253227 seconds)
2021-02-04 18:30:58 | INFO | fairseq_cli.train | end of epoch 16 (average epoch stats below)
2021-02-04 18:30:58 | INFO | train | epoch 016 | loss 2.322 | nll_loss 0.465 | ppl 1.38 | wps 12046 | ups 3.57 | wpb 3371.3 | bsz 796.4 | num_updates 1881 | lr 2.35125e-05 | gnorm 1.847 | loss_scale 1 | train_wall 22 | wall 664
2021-02-04 18:30:58 | INFO | fairseq_cli.train | begin training epoch 16
2021-02-04 18:31:01 | INFO | train_inner | epoch 017:     19 / 118 loss=2.315, nll_loss=0.458, ppl=1.37, wps=11538.3, ups=3.39, wpb=3406.7, bsz=813.3, num_updates=1900, lr=2.375e-05, gnorm=1.783, loss_scale=1, train_wall=19, wall=668
2021-02-04 18:31:20 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:31:21 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:31:21 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:31:21 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is a fast-acting insulin and can be used together with long-acting insulin products.
2021-02-04 18:31:21 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:31:22 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy and is usually reversible.
2021-02-04 18:31:22 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:31:25 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was evaluated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide with a human insulin analogue (insulin Aspart) by measuring for six months the level of a substance in the blood called glycosylated haemoglobin (HbA1c) that indicates how well blood glucose is controlled. What benefit has actrapide shown in these trials? HbA1c concentrations remain relatively stable during 6 months of treatment with actrapide.
2021-02-04 18:31:25 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:31:25 | INFO | valid | epoch 017 | valid on 'valid' subset | loss 4.03 | nll_loss 2.328 | ppl 5.02 | bleu 41.22 | wps 898.9 | wpb 1083 | bsz 37.8 | num_updates 1999 | best_bleu 42.07
2021-02-04 18:31:25 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:31:31 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 17 @ 1999 updates, score 41.22) (writing took 6.1394816897809505 seconds)
2021-02-04 18:31:31 | INFO | fairseq_cli.train | end of epoch 17 (average epoch stats below)
2021-02-04 18:31:31 | INFO | train | epoch 017 | loss 2.3 | nll_loss 0.442 | ppl 1.36 | wps 11970.4 | ups 3.55 | wpb 3371.3 | bsz 796.4 | num_updates 1999 | lr 2.49875e-05 | gnorm 1.807 | loss_scale 1 | train_wall 22 | wall 697
2021-02-04 18:31:31 | INFO | fairseq_cli.train | begin training epoch 17
2021-02-04 18:31:31 | INFO | train_inner | epoch 018:      1 / 118 loss=2.302, nll_loss=0.446, ppl=1.36, wps=11341.3, ups=3.35, wpb=3385.4, bsz=798.5, num_updates=2000, lr=2.5e-05, gnorm=1.867, loss_scale=1, train_wall=19, wall=698
2021-02-04 18:31:50 | INFO | train_inner | epoch 018:    101 / 118 loss=2.284, nll_loss=0.423, ppl=1.34, wps=17606.7, ups=5.28, wpb=3333.2, bsz=789.3, num_updates=2100, lr=2.625e-05, gnorm=1.676, loss_scale=1, train_wall=19, wall=717
2021-02-04 18:31:53 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:31:54 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:31:54 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:31:55 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:31:55 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:31:56 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-04 18:31:56 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:31:58 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was evaluated in patients with type 1 diabetes, in whom the pancreas is unable to produce insulin (two trials with 1,954 patients), and in patients with type 2 diabetes, in whom the body is unable to process insulin effectively (a trial with 182 patients). Actrapide was compared with a human insulin analogue (insulin Aspart) in that for six months the concentration of a substance in the blood called glycosylated haemoglobin (HbA1c), which indicates how well blood glucose is controlled, was measured. What benefit did Actrapide show in these trials? HbA1c concentrations remained relatively stable during 6 months of treatment with Actrapide.
2021-02-04 18:31:58 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:31:58 | INFO | valid | epoch 018 | valid on 'valid' subset | loss 3.962 | nll_loss 2.262 | ppl 4.8 | bleu 41 | wps 851.4 | wpb 1083 | bsz 37.8 | num_updates 2117 | best_bleu 42.07
2021-02-04 18:31:58 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:32:05 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 18 @ 2117 updates, score 41.0) (writing took 6.705550093203783 seconds)
2021-02-04 18:32:05 | INFO | fairseq_cli.train | end of epoch 18 (average epoch stats below)
2021-02-04 18:32:05 | INFO | train | epoch 018 | loss 2.275 | nll_loss 0.414 | ppl 1.33 | wps 11671.5 | ups 3.46 | wpb 3371.3 | bsz 796.4 | num_updates 2117 | lr 2.64625e-05 | gnorm 1.61 | loss_scale 1 | train_wall 22 | wall 732
2021-02-04 18:32:05 | INFO | fairseq_cli.train | begin training epoch 18
2021-02-04 18:32:21 | INFO | train_inner | epoch 019:     83 / 118 loss=2.238, nll_loss=0.374, ppl=1.3, wps=11431.7, ups=3.23, wpb=3538.2, bsz=829.4, num_updates=2200, lr=2.75e-05, gnorm=1.408, loss_scale=1, train_wall=19, wall=748
2021-02-04 18:32:27 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:32:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:32:28 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:32:29 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:32:29 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:32:30 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy that is usually reversible.
2021-02-04 18:32:30 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:32:32 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was evaluated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The trials compared Actrapide to a human insulin analogue (insulin Aspart) by measuring in the blood for six months a substance known as glycosylated haemoglobin (HbA1c) that indicates how well blood glucose is controlled. What benefit has actrapide shown in these trials?
2021-02-04 18:32:32 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:32:32 | INFO | valid | epoch 019 | valid on 'valid' subset | loss 3.987 | nll_loss 2.29 | ppl 4.89 | bleu 40.56 | wps 917 | wpb 1083 | bsz 37.8 | num_updates 2235 | best_bleu 42.07
2021-02-04 18:32:32 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:32:39 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 19 @ 2235 updates, score 40.56) (writing took 7.173689816147089 seconds)
2021-02-04 18:32:39 | INFO | fairseq_cli.train | end of epoch 19 (average epoch stats below)
2021-02-04 18:32:39 | INFO | train | epoch 019 | loss 2.259 | nll_loss 0.398 | ppl 1.32 | wps 11619.7 | ups 3.45 | wpb 3371.3 | bsz 796.4 | num_updates 2235 | lr 2.79375e-05 | gnorm 1.615 | loss_scale 1 | train_wall 22 | wall 766
2021-02-04 18:32:39 | INFO | fairseq_cli.train | begin training epoch 19
2021-02-04 18:32:52 | INFO | train_inner | epoch 020:     65 / 118 loss=2.28, nll_loss=0.422, ppl=1.34, wps=10728.3, ups=3.26, wpb=3293, bsz=808, num_updates=2300, lr=2.875e-05, gnorm=1.759, loss_scale=1, train_wall=19, wall=778
2021-02-04 18:33:02 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:33:02 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:33:02 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:33:03 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide is fast-acting insulin and can be used together with long-acting insulin products.
2021-02-04 18:33:03 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:33:04 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may result in discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-04 18:33:04 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:33:06 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was investigated in patients with type 1 diabetes in whom the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in whom the body is unable to process insulin effectively (a trial with 182 patients) .The studies compared Actrapide to a human insulin analogue (insulin Aspart) by measuring in the blood for six months a substance called glycosylated haemoglobin (HbA1c) that indicates how well blood glucose is controlled. What benefit has Actrapide shown in these trials? concentrations of HbA1c have remained relatively stable during the 6 months of treatment with Actrapide.
2021-02-04 18:33:06 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:33:06 | INFO | valid | epoch 020 | valid on 'valid' subset | loss 3.988 | nll_loss 2.298 | ppl 4.92 | bleu 41.3 | wps 906.4 | wpb 1083 | bsz 37.8 | num_updates 2353 | best_bleu 42.07
2021-02-04 18:33:06 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:33:15 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_1/checkpoint_last.pt (epoch 20 @ 2353 updates, score 41.3) (writing took 8.637247344478965 seconds)
2021-02-04 18:33:15 | INFO | fairseq_cli.train | end of epoch 20 (average epoch stats below)
2021-02-04 18:33:15 | INFO | train | epoch 020 | loss 2.243 | nll_loss 0.38 | ppl 1.3 | wps 11137.1 | ups 3.3 | wpb 3371.3 | bsz 796.4 | num_updates 2353 | lr 2.94125e-05 | gnorm 1.496 | loss_scale 1 | train_wall 22 | wall 802
2021-02-04 18:33:15 | INFO | fairseq_cli.train | done training in 792.1 seconds


###############################################################################
Peregrine Cluster
Job 17828721 for user 's3475743'
Finished at: Thu Feb  4 18:33:19 CET 2021

Job details:
============

Job ID              : 17828721
Name                : EMEA_p_4_1
User                : s3475743
Partition           : gpu
Nodes               : pg-gpu33
Number of Nodes     : 1
Cores               : 12
State               : COMPLETED
Submit              : 2021-02-04T17:27:58
Start               : 2021-02-04T18:19:10
End                 : 2021-02-04T18:33:19
Reserved walltime   : 23:55:00
Used walltime       : 00:14:09
Used CPU time       : 00:15:26 (efficiency:  9.09%)
% User (Computation): 61.55%
% System (I/O)      : 38.45%
Mem reserved        : 32G/node
Max Mem used        : 5.60G (pg-gpu33)
Max Disk Write      : 40.96K (pg-gpu33)
Max Disk Read       : 2.30M (pg-gpu33)
Average GPU usage   : 55.4% (pg-gpu33)


Acknowledgements:
=================

Please see this page for information about acknowledging Peregrine in your publications:

https://wiki.hpc.rug.nl/peregrine/introduction/scientific_output

################################################################################
